What are the Treatment Options for Patients With Lenalidomide-Refractory Myeloma? – MashupMD

Blood Cancers Today

Oncology / Hematology

Blood Cancers Today is a property that provides hematologists and oncologists with news, education, and information relevant to their patients and practices, with insight from experts in the field. As the online home of the publication, bloodcancerstoday.com is updated daily, with the most current information from around the specialty and multimedia content, including exclusive interviews with presenters at major medical meetings.

Articles

Mashup Score: 11

What are the Treatment Options for Patients With Lenalidomide-Refractory Myeloma? | Blood Cancers Today - 1 year(s) ago

Donna Catamero, ANP-BC, OCN, CCRC, discusses selinexor for myeloma, the BOSTON trial, and other recent advances in myeloma.

Source: bloodcancerstoday.com

Categories: General Medicine News, Partners & KOLs

Tweet Tweets with this article
- Blood_Cancers
  
  Donna Catamero, ANP-BC, OCN, CCRC (@domenica76), of @IcahnMountSinai, stopped by BCT to discuss the efficacy and toxicity management of selinexor, results from the BOSTON trial, and other recent advances in #myeloma. 📺 Watch her interview here! https://t.co/mLoBgsiTXc https://t.co/sdCPZrcZ6a

Mashup Score: 3

What Is the Role of Splenic Irradiation Before HSCT in Patients With MF? | Blood Cancers Today - 1 year(s) ago

Splenic irradiation before HSCT is associated with reduced spleen size and lower incidence of relapse in patients with MF.

Source: bloodcancerstoday.com

Categories: General Medicine News, Partners & KOLs

Tweet Tweets with this article
- Blood_Cancers
  
  Splenic irradiation before HSCT is associated with reduced spleen size and lower incidence of relapse in patients with #myelofibrosis. Read more about the study, led by @NicoGagelmann, of @UKEHamburg, and published in @AjHematology. 📰 https://t.co/miBqTylIH7 https://t.co/GEd0iiG0mf

Mashup Score: 21

Unanswered Questions in MDS at ‘The HemOnc Pulse’ Live 2024 in Chicago | Blood Cancers Today - 1 year(s) ago

The panel mainly focused on how to define and classify myelodysplastic syndromes and clonal hematopoiesis of indeterminate potential.

Source: bloodcancerstoday.com

Categories: General Medicine News, Partners & KOLs

Tweet Tweets with this article
- Blood_Cancers
  
  Out now! 🥳 The #MDS panel from #HOPLive24 discusses: ☑️ How to classify and define MDS and CHIP ☑️ How to treat low- and high-risk MDS ☑️ How to approach transplant Check it out! https://t.co/TjZoRLTW2y @Ramikomrokji @Dr_AmerZeidan @drsangeetmd @sanamloghavi @chadinabhan https://t.co/YCj0AJ1oqq